$IQV

Berkshire James G. sold $697K of IQV

Berkshire James G. (See Remarks) sold 2,668 shares of IQVIA HOLDINGS INC. (IQV) at $261.33 ($0.70M total) on 2026-09-02.

Original reporting
SEC EDGAR · Berkshire James G.
Published Sep 4, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Bearish
medium confidence
Mentioned
$IQV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, making it a primary source.

02

Market read

Small insider sale; limited trading impact but worth noting for short-term sentiment.

03

What to watch

No disclosed 10b5‑1 plan; insider may have personal liquidity needs.

Relevance 5/10Novelty 4/10Timing: filed Sep 4, 2026

Background

Form 4 filings disclose insider transactions; traders monitor them for sentiment cues.

Company-level read

Ticker impact

$IQVBearishMedium confidence
Context

Officer James G. Berkshire sold 2,668 shares of IQVIA for $697,228, reducing his stake to 10,890 shares.

Expected impact

Modest downward pressure; price may dip 1‑2% in the next trading session.

Evidence & confidence

Sale size is modest relative to market cap, but insider sales often attract short-term traders.

Market effects

Minimal impact on healthcare data analytics sector.

U.S. market only.

Low

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • IQVIA Holdings Inc.

    Provider of health information technology and data analytics.

  • James G. Berkshire

    Company officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 8/10

IQVIA Holdings (IQV) Prices $2b In Senior Notes, Is The Stock Still Undervalued?

IQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.

$IQVMed

Learn Why The Bull Case For IQVIA (IQV) Could Change Following AI Trial Platform Launch

IQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.

$IQVHighAI 8/10

IQVIA stock rises amid $2 billion senior notes offering

IQVIA Holdings Inc. (IQV) shares rose 4.3% after announcing a $2 billion senior notes offering due 2034, with a 6.375% interest rate. Proceeds will redeem existing notes, repay debt, and cover offering fees. The offering is expected to close by September 23, 2026, and is targeted at institutional buyers and non-U.S. investors. IQVIA is a global provider of clinical research and healthcare intelligence services.